ArticleAmerican heart journal2016
Protocol for analyses of adverse event data from randomized controlled trials of statin therapy.
Article in American heart journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.Lancet (London, England) · 2026Pooled it
- Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.The lancet. Diabetes & endocrinology · 2024 · on this mapPooled it
- Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.Clinical trials (London, England) · 2022Pooled it
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.Lancet (London, England) · 2022 · on this mapPooled it
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.Lancet (London, England) · 2019Pooled it
- The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs.Health technology assessment (Winchester, England) · 2021Trial
- Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials.BMJ (Clinical research ed.) · 2021Trial
- Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.BMC nephrology · 2017Trial
- Article
- Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients.BMJ open · 2021 · on this mapArticle
- Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs.Current oncology reports · 2021Review
- Sponsorship bias in clinical trials: growing menace or dawning realisation?Journal of the Royal Society of Medicine · 2020Review
- Statin use and the risk of acute kidney injury in older adults.BMC nephrology · 2019Article
- RNAi technique, how far is it from pediatrics?Pediatric investigation · 2017Article
- Statin withdrawal in people with dementia.The Cochrane database of systematic reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The Cholesterol Treatment Trialists' (CTT) Collaboration was originally established to conduct individual participant data meta-analyses of major vascular events, cause-specific mortality, and site-specific cancers in large, long-term, randomized trials of statin therapy (and other cholesterol-modifying treatments). The results of the trials of statin therapy and their associated meta-analyses have shown that statins significantly reduce the risk of major vascular events without any increase in the risk of nonvascular causes of death or of site-specific cancer, but do produce small increases in the incidence of myopathy, diabetes, and, probably, hemorrhagic stroke. The CTT Collaboration has not previously sought data on other outcomes, and so a comprehensive meta-analysis of all adverse events recorded in each of the eligible trials has not been conducted. This protocol prospectively describes plans to extend the CTT meta-analysis data set so as to provide a more complete understanding of the nature and magnitude of any other effects of statin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.